...
首页> 外文期刊>Infectious diseases in clinical practice: IDCP >Empiric Pharmacodynamic Performance of 9 Antimicrobials Against Pathogens Implicated in the Cause of Complicated Skin and Soft Tissue Infections A Report From the OPTAMA Program
【24h】

Empiric Pharmacodynamic Performance of 9 Antimicrobials Against Pathogens Implicated in the Cause of Complicated Skin and Soft Tissue Infections A Report From the OPTAMA Program

机译:9种抗病原体涉及复杂皮肤和软组织感染的病原体的经验药效学性能OPTAMA计划的报告

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: We compared the probability of achieving bactericidal exposure for commonly used intravenous antibiotics against the pathogens causing complicated skin and soft tissue infections (cSSTIs) to assist in the decision process for initial empiric therapy.Methods: The minimum inhibitory concentration values (MICs) for methicillin-susceptible Staphylococcus aureus, Pseudomonas aeru-ginosa, Escherichia coli, Enterobacter spp, and Klebsiella spp were collected from the 2004 MYSTIC surveillance study in US hospitals, and weighted by their prevalence in causing SSTI Pharmacodynamic exposures were simulated in 5000 subjects receiving inu'penem,meropenem, ertapenem, piperacillin-tazobactam,ceftriax-one, ceftazidime, cefepime, ciprofloxacin, and levofloxacin against these pathogens to calculate the cumulative fraction of response (CFR). Pharmacodynamic end points evaluated included f T>MICfor the beta-lactams and/AUC/MIC for fluoroquinolones The prevalence of methicillin-resistant S aureus (MRSA) was later added into the model at increasing rates to determine its overall effect on CFR.Results: Cefepime 2 g qI2h, imipenem 500 mg and 1 g q8h, meropenem 500 mg and 1 g q8h, and piperacillin-tazobactam 3 375 g q6h achieved greater than 90% CFR in the absence of MRSA Third-generation cephalosporins, quinolones, and ertapenem achieved rates of only 34 8-48 9%, 55 3-75 1%, and 87 8%, respectively No antimicrobial achieved acceptable CFR when MRSA prevalence exceeded >10% in the model.Conclusion: Due to increasing resistance rates among commonly encountered pathogens and the inability to provide optimal drug exposure, third-generation cephalosporins, fluoroquinolones, and ertapenem should be avoided for the empiric treatment of cSSIIs in place of more broad-spectrum therapy The addition of an anti-MRSA agent is recommended when this phenotype is suspected.
机译:目的:我们比较了常用静脉内抗生素对引起复杂皮肤和软组织感染(cSSTIs)的病原体的杀菌暴露的可能性,以协助初步经验疗法的决策过程。方法:最小抑菌浓度值(MICs)耐甲氧西林的金黄色葡萄球菌,铜绿假单胞菌,大肠杆菌,肠杆菌属和克雷伯菌属是从2004年在美国医院进行的MYSTIC监测研究中收集的,并按其引起SSTI的流行程度加权,对5000名接受inu'青霉烯,美罗培南,厄他培南,哌拉西林-他唑巴坦,头孢噻肟-one,头孢他啶,头孢吡肟,环丙沙星和左氧氟沙星对这些病原体的累积反应分数(CFR)。评估的药效学终点包括β-内酰胺的f T> MIC和氟喹诺酮类的/ AUC / MIC。耐甲氧西林金黄色葡萄球菌(MRSA)的患病率随后以增加的速率添加到模型中,以确定其对CFR的总体影响。在没有MRSA的情况下,头孢吡肟2 g qI2h,亚胺培南500 mg和1 g q8h,美罗培南500 mg和1 g q8h,哌拉西林-他唑巴坦3375 g q6h的CFR均大于90%,实现了第三代头孢菌素,喹诺酮和厄他培南率分别仅为34 8-48 9%,55 3-75 1%和87 8%当模型中的MRSA流行率超过10%时,没有抗菌药物达到可接受的CFR结论:由于常见病原体的耐药率增加并应避免无法提供最佳的药物暴露,cSSIIs的经验性治疗应替代第三代头孢菌素,氟喹诺酮和厄他培南,而不是采用更广谱的治疗方法。建议使用抗MRSA药物在该表型被怀疑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号